Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity.
Level 5 - mechanism / opinion, no new human data
In vitro bench research and high-throughput drug screening without animal or human subject data.
PubMed 20508255 · doi:10.1177/1087057110370998
What was done
An in vitro cell-based enzyme-linked immunosorbent assay (ELISA) was developed in a primary astrocyte cell line engineered to detect modulators of glial glutamate transporter (EAAT2) translation. A library of approximately 140,000 compounds was screened. Initial hits were re-evaluated across three concentrations to assess dose dependency, and select compounds were characterized via 12-point dose-response curves and confirmed using Western blot, immunohistochemistry, and functional glutamate uptake assays.
What was found
The initial screen yielded 293 candidate hits from the ~140,000 compounds. Secondary testing at three concentrations identified 61 compounds that produced a dose-dependent increase in EAAT2 protein levels. Follow-up assays on selected compounds confirmed elevated EAAT2 protein expression, correct cellular localization, and functional increases in glutamate clearance, though specific numerical potency values (such as EC50 or fold-increases) were not reported in the abstract.
Why it matters
Pharmacological upregulation of EAAT2 translation represents a potential strategy to prevent excitotoxicity in stroke, trauma, ALS, and Alzheimer's disease. This screen provides 61 candidate molecules that serve as chemical starting points for neuroprotective drug development.
Limits
The study is entirely in vitro, providing no data on in vivo efficacy, blood-brain barrier permeability, cytotoxicity, or pharmacokinetic properties. The abstract does not provide quantitative metrics for compound potency, efficacy, or specific chemical scaffolds identified.
Cited by
- supports Excitotoxicity is an established pathological factor in stroke, traumatic brain injury, ALS, Parkinson's disease, and Alzheimer's disease.